ArticleFrontiers in oncology2022

Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response.

Yihui Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.